Dr. Reddy'S Laboratories (RDY) analyst forecast and price target
Analyst forecast
Consensus of 41 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HSBC | Upgraded | Hold → Buy | $16.90 from $14.44 | Jun 5, 2025 |
| Barclays | Maintained | Overweight | $17.00 from $17.40 | Nov 6, 2024 |
| Barclays | Maintained | Overweight | $87.00 from $81.00 | Jul 30, 2024 |
| Barclays | Maintained | Overweight | $81.00 from $80.00 | May 8, 2024 |
| Barclays | Maintained | Overweight | $80.00 from $75.00 | Jan 29, 2024 |
| Barclays | Maintained | Overweight | $70.00 from $67.00 | Jun 1, 2023 |
Frequently asked questions
Is RDY a buy, sell, or hold?
Analysts covering Dr. Reddy'S Laboratories currently average a Buy rating: 17 buy, 11 hold and 13 sell, from 41 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on RDY?
On Jun 5, 2025, HSBC upgraded Dr. Reddy'S Laboratories to Buy with a price target of $16.90.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.